Authors
Ben Killingley, Alex J Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie Zhou, Kate Lindsell, Samanjit S Hare, Jonathan Brown, Rebecca Frise, Emma Smith, Claire Hopkins, Nicolas Noulin, Brandon Löndt, Tom Wilkinson, Stephen Harden, Helen McShane, Mark Baillet, Anthony Gilbert, Michael Jacobs, Christine Charman, Priya Mande, Jonathan S Nguyen-Van-Tam, Malcolm G Semple, Robert C Read, Neil M Ferguson, Peter J Openshaw, Garth Rapeport, Wendy S Barclay, Andrew P Catchpole, Christopher Chiu
Publication date
2022/5
Journal
Nature Medicine
Volume
28
Issue
5
Pages
1031-1041
Publisher
Nature Publishing Group
Description
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of cases and continues to circulate globally. To establish a novel SARS-CoV-2 human challenge model that enables controlled investigation of pathogenesis, correlates of protection and efficacy testing of forthcoming interventions, 36 volunteers aged 18–29 years without evidence of previous infection or vaccination were inoculated with 10 TCID 50 of a wild-type virus (SARS-CoV-2/human/GBR/484861/2020) intranasally in an open-label, non-randomized study (ClinicalTrials. gov identifier NCT04865237; funder, UK Vaccine Taskforce). After inoculation, participants were housed in a high-containment quarantine unit, with 24-hour close medical monitoring and full access to higher-level clinical care. The study’s primary objective was to identify an inoculum dose that induced well-tolerated …
Total citations
Scholar articles
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022